Ion Channel Consortium for Ion Channel Drug Discovery formed by Aurora, Alion Pharmaceuticals and Specs
Vancouver, British Columbia, February 14, 2012
Aurora Biomed Inc. is pleased to announce that it has signed an agreement with Alion Pharmaceuticals and Specs to form a new Ion Channel Consortium that will provide a novel, comprehensive solution for ion channel drug discovery. Together, the three companies will offer value added identification and validation of ion channel modulators. The Ion Channel Consortium combines Alion’s proprietary method for short-listing drug candidates, Specs’ reliable sourcing and synthesis of compounds, and Aurora’s superior patch clamp services. Researchers now have an option that enables time and cost savings while providing a unique method to identify new drug candidates for channel opathies.
About Aurora Biomed
Aurora Biomed is a global leader in the design and development of laboratory solutions for life science, environmental science, drug discovery/safety and chemical analysis research. We are committed to improving the quality of human and environmental health by providing technology and services which facilitate a higher sample throughput while improving quality, accuracy and precision. Aurora Biomed focuses on ion channel screening services for drug discovery and innovative high-throughput ion channel screening technology. Aurora’s proprietary ion channel readers enable the pharmaceutical industry to address drug safety issues earlier in the discovery process. Aurora Biomed provides contract research services for ion channels, channel forming proteins and toxins, creation and testing of mutant cDNA ion channels, and various ion channel cell lines.
About Specs
Specs is one of the world''s leading suppliers of chemistry solutions for drug discovery to the Life Science industry. The main activities of Specs are focused on the supply of large numbers of high-quality screening compounds for High Throughput Screening (HTS), on-site and/or off-site compound handling, cheminformatics and contract research for lead discovery programs. Equipped with state-of-the-art technology and world-class expertise, Specs provides custom-tailored services and breakthrough solutions for the pharmaceutical, biotech and agrochemical industry worldwide, allowing the customers to concentrate on the development of their core (research) activities. Information about Specs can be found at www.specs.net
About Alion Pharmaceuticals
Alion has developed proprietary in silico technology to rapidly identify lead compounds to modulate certain ion channels and protein-protein interactions. The technology is applicable to designing small molecule leads for specific ion channels. Short-listed, high value compounds can then have their effect on ion channels characterized through limited experimentation. Alion’s technology is applicable to designing small molecule leads to a given macro-molecule target, where only the structure of a peptide (or protein) ligand is known.
Aurora、 Alion Pharmaceuticals 、 Specs離子通道（藥物開發）聯盟成立！
加拿大卑斯省，溫哥華，2012-02-14
Aurora（歐羅拉）公司榮幸地宣布：我司與Alion Pharmaceuticals公司以及Specs公司正式簽署協議，共同成立一個新的離子通道科研技術聯盟，致力于向藥物研發產業貢獻更新穎、更完善的技術方案！同心協力，此三方聯盟將進一步增強離子通道調制器技術極具價值的（元素）識別和確認功能。新離子通道聯盟結合了Alion公司專有的藥物初選方法，Specs公司可靠的化合物元素識別和合成技術，以及Aurora優越的膜片鉗技術。科研人員將獲得省時、經濟又獨到的方案以進行新藥物的識別和篩選工作。
Aurora公司是全球科研方案設計開發方面的領頭企業。我司產品及技術覆蓋生命科學、環境科學、藥品研究與安全監控，以及化學元素分析研究等多個領域，集研發與生產于一體，連科研與應用于一線。我們以提高人與環境的健康狀況為使命，提供高通量并且高質、精確、精準的科學技術與服務。Aurora公司專注于藥物研發方面的離子通道篩選技術以及創新高通量離子通道篩選技術，其**的離子通道閱讀器為制藥業在研發初期發現并關注藥品安全因素提供了可能性。除此以外，Aurora公司還樂意提供離子通道，通道蛋白和病毒，突變基因離子通道的設立和檢測，和各種細胞株離子通道方面的合同研究服務。
Specs公司是一家為生命科學行業的藥物開發提供化學解決方案的著名供應商。該公司主營業務是為大研究項目提供各類高品質的合成藥物，以進行高通量篩選，現場或非現場的藥物處理，化學信息學處理及合同研究等應用。Specs公司擁有國家最先進的技術和世界一流的專家，為客戶提供個性化服務，并為全球制藥、生物技術和農藥行業提供具有突破性的解決方案，讓研究者將寶貴的時間和精力投入到更有創造性的工作中。詳細信息請瀏覽www.specs.net
Alion公司已經開發了特有的硅片技術，可迅速地識別靶標化合物來調節某些離子通道和蛋白質的相互作用。該公司的技術適用于針對特殊離子通道設計小分子靶向藥物，縮小了篩選范圍，而那些有價值的化合物通過少量試驗則可用離子通道定性。Alion公司的技術還適用于針對已知的目標物設計只知道多肽（蛋白質）結構的小分子靶向藥物。